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One-carbon metabolism and depression
Kim et al concluded that lower levels of folate and vitamin B12 and
raised homocysteine may be risk factors for late-life depression.1
We propose to include polyunsaturated fatty acids (PUFAs) in
future studies that will test the potential role of one-carbon
metabolism in the aetiology and persistence of depression, for
several reasons. First, because one-carbon metabolism is
intimately linked with PUFA metabolism.2 The methionine–
homocysteine cycle produces methyl groups for the synthesis of
phosphatidylcholine from phosphatidylethanolamine catalysed
by phosphatidylethanolamine methyltransferase. Phosphatidyl-
choline is critical for the delivery of important PUFAs such as
docosahexaenoic acid (DHA; C22:6n-3) from the liver to the
plasma and distribution to peripheral tissues. The phosphatidyl-
choline/phosphatidylethanolamine ratio also modulates the
activity of Delta-5 and Delta-6 desaturases involved in n-3 and
n-6 PUFA synthesis. Moreover, plasma homocysteine was
significantly inversely correlated with DHA, total n-3 PUFAs
and the n-3/n-6 PUFA ratio in healthy males.3 Second, these
findings are relevant for psychiatry, as PUFAs – particularly
DHA and arachidonic acid – are key ‘building stones’ that are
required for healthy functioning of nerve and brain cells. In
patients with recurrent depression, a decrease in n-3 PUFAs in
erythrocyte membranes was found together with a significant
positive association between the sum of plasma n-6 PUFAs and
homocysteine.4 There is also increasing evidence from cross-
sectional studies and randomised controlled trials supporting
the notion that an impaired PUFA metabolism is directly linked
to the onset of depression.5,6 Third, both an impaired one-carbon
and an impaired PUFA metabolism might explain the positive
associations between depression and metabolic syndrome (a
cluster of risk factors for cardiovascular disease). Patients with
depression are at risk for all components of metabolic syndrome.
Interestingly, metabolic syndrome is associated with a rise in
plasma homocysteine levels and a decrease in DHA in plasma
and cell membranes. Based on these findings, our opinion is that
for a proper understanding of underlying mechanisms linking
one-carbon metabolism and depression, homocysteine, folate
and B-vitamins should be measured in conjunction with dietary
and laboratory analyses of PUFAs.
1 Kim JM, Stewart R, Kim SW, Yang SJ, Shin IS, Yoon JS. Predictive value
of folate, vitamin B12 and homocysteine levels in late-life depression.
Br J Psychiatry 2008; 192: 268–74.
2 Selley ML. A metabolic link between S-adenosylhomocysteine and
polyunsaturated fatty acid metabolism in Alzheimer’s disease. Neurobiol
Aging 2007; 28: 1834–9.
3 Li D, Mann NJ, Sinclair AJ. A significant inverse relationship between
concentrations of plasma homocysteine and phospospholipid
docosahexaenoic acid in healthy male subjects. Lipids 2006; 41: 85–95.
4 Assies J, Lok A, Bockting CL, Weverling GJ, Lieverse R, Visser I, Abeling NGGM,
Duran M, Schene A. Fatty acids and homocysteine levels in patients with
recurrent depression: an explorative pilot study. Prostaglandins Leukot
Essent Fatty Acids 2004; 70: 349–56.
5 Severus WE, Litman AB, Stoll AL. Omega 3 fatty acids, homocysteine, and the
increased cardiovascular mortality in major depressive disorder. Harv Rev
Psychiatry 2001; 9: 280–93.
6 Pouwer F, Nijpels G, Beekman AT, Dekker JM, van Dam RJ, Heine RJ, Snoek
FJ. Fat food for a bad mood. Can we treat and prevent depression in type 2
diabetes by means of Omega-3 polyunsaturated fatty acids? Diabet Med
2005; 22: 1465–75.
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Authors’ reply: As Assies & Pouwer appropriately point out,
there has been growing evidence for an underlying metabolic link
between the key components of one-carbon metabolism and
PUFAs both in depression and dementia.1 However, we do not
fully agree with their recommendation for measuring these factors
in combination. Our reasons are as follows. One of the main
potential mood stabilising effects of PUFAs in depression is
thought to be their dampening action against abnormal intra-
cellular signal transduction by (a) inhibiting G-protein-mediated
and phospholipase-C-mediated hydrolysis of crucial membrane
phospholipids;2 (b) modulating the influx of calcium ions;3 and
(c) reducing the activity of protein kinase C.4 In addition, PUFA
actions are closely related to inflammatory and immune pathways,
which are also potentially important in the pathogenesis of
depression.5 Compared with these more established findings, the
evidence for relationships between one-carbon metabolism and
PUFAs in depression is relatively scant. For these reasons, we
cannot recommend measuring PUFAs in the context of
one-carbon metabolism at the present time, particularly for
clinical purposes. However, we do feel that Assises & Pouwer’s
suggestions should encourage future animal and clinical studies
on these interesting research issues.
1 Das UN. Folic acid and polyunsaturated fatty acids improve cognitive
function and prevent depression, dementia, and Alzheimer’s disease – but
how and why? Prostaglandins Leukot Essent Fatty Acids 2008; 78: 11–9.
2 Sperling RI, Benincaso AI, Knoell CT, Larkin JK, Austen KF, Robinson DR.
Dietary omega-3 polyunsaturated fatty acids inhibit phosphoinositide
formation and chemotaxis in neutrophils. J Clin Invest 1993; 91: 651–60.
3 Honen BN, Saint DA, Laver DR. Suppression of calcium sparks in rat
ventricular myocytes and direct inhibition of sheep cardiac RyR channels by
EPA, DHA and oleic acid. J Membr Biol 2003; 196: 95–103.
4 Seung Kim HF, Weeber EJ, Sweatt JD, Stoll AL, Marangell LB. Inhibitory
effects of omega-3 fatty acids on protein kinase C activity in vitro. Mol
Psychiatry 2001; 6: 246–8.
5 Maes M, Smith RS. Fatty acids, cytokines, and major depression. Biol
Psychiatry 1998; 43: 313–4.
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Risk of harm after psychological intervention
In their trial of cognitive–behavioural therapy (CBT) and family
intervention for relapse prevention in psychosis,1 Garety et al
state: ‘There were no differences between the groups, in either
[the no-carer or carer] pathway, in the primary outcomes of
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patterns of remission and relapse’. However, data in their Table 1
indicates that more patients who received CBT relapsed than those
who received treatment as usual (TAU) (CBT 60/122, TAU 41/119
for all the patients randomised to CBT or TAU). A statistical
analysis (logistic model) for the proportion of relapses reveals a
significant reduced relapse frequency for TAU.
The differences remain significant (P=0.0153) when only
patients in the no-carer pathway are considered (CBT 53/97,
TAU 34/92), but there are no differences for those in the carer
pathway (CBT 7/25, TAU 7/27), although here the numbers are
small.
It is possible that differences in gender and age distribution
between the CBT and TAU arms of the trial, or even differences
between centres, could have led to different results in the statistical
analyses performed by the authors. However, randomisation
should have minimised such differences and the authors make
no mention of them in the paper.
Hence, on the basis of the results reported, CBT appears to
have a detrimental effect on relapse in non-affective psychosis.
1 Garety PA, Fowler DG, Freeman D, Bebbington P, Dunn G, Kuipers E.
Cognitive–behavioural therapy and family intervention for relapse prevention
and symptom reduction in psychosis: randomised controlled trial. Br J
Psychiatry 2008; 192: 412–23.
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of Hertfordshire, UK
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The paper by Garety et al1 was an extremely important and
methodologically robust examination of the impact of psycho-
social interventions for schizophrenia. The editorial by Scott2 in
the same issue suggested that there has been an overpromise of
CBT and the inclusion in the National Institute for Health and
Clinical Excellence (NICE)3 guideline might have been oversold
as there was a lack of evidence of efficacy in schizophrenia. There
are several points which need to be added to those discussed in the
paper and in the editorial.
The hypothesis used to calculate power was based on the
primary outcome of relapse from a non-affective psychosis
(ICD–10 category F20–29, and not F2 as reported in the paper),
using TAU, CBT for psychosis and family intervention as com-
parison interventions. It is therefore important to focus on this
outcome and it is surprising that this was not analysed in greater
detail.
The published relapse rates after full remission and from full/
partial remission in the no-carer pathway were 35.4% and 37%
respectively for TAU and 46.8% and 54.6% respectively for CBT;
in the carer pathways they were 21.4% and 25.9% for TAU,
27.3% and 28% for CBT, 22.2% and 20.8% for family interven-
tion. It would have been important to analysis the pathways sepa-
rately as the no-carer pathway shows a trend for an increase in
relapse rates. This was indeed the statistical evaluation in the semi-
nal personal therapy/family therapy 3-year study by Hogarty et al,4
where offering therapeutic intervention in a no-carer pathway led
to significantly increased rates of psychotic relapse. The discussion
in the published paper was thus incorrect in the assertion that the
effect of having a carer during psychological intervention had not
been reported before.
The second table of results showed the mean number of
relapses in the no-carer pathway: 0.79 for TAU and 1.17 for
CBT; for the carer pathway this was 0.31 for TAU, 0.63 for CBT
and 0.96 for family intervention. The relapse rates point towards
an increase in hypothesised outcome and the risk of harm or
hazard5 needs to have been discussed in greater detail, to give
balance to what has already been acknowledged to be an oversold
intervention.
1 Garety PA, Fowler DG, Freeman D, Bebbington P, Dunn G, Kuipers E.
Cognitive–behavioural therapy and family intervention for relapse prevention
and symptom reduction in psychosis: randomised controlled trial.
Br J Psychiatry 2008; 192: 412–23.
2 Scott J. Cognitive–behavioural therapy for severe mental disorders: back to
the future? Br J Psychiatry 2008; 192: 401–3.
3 National Institute for Health and Clinical Excellence. Schizophrenia: Core
interventions in the Treatment and Management of Schizophrenia in Primary
and Secondary Care. NICE, 2003.
4 Hogarty GE, Kornblith SJ, Greenwald D, DiBarry AL, Cooley S, Ulrich RF,
Carter M, Flesher S. Three years trials of personal therapy with
schizophrenics living with or independent of family. I: Description of study
and effects on relapse rates. Am J Psychiatry 1997; 154: 1504–13.
5 Marlowe KH. Early interventions for psychosis. Br J Psychiatry 2005; 186:
262–3.
Karl Marlowe, Tower Hamlets’ Early Intervention Service, East London NHS
Foundation Trust, London, UK. Email: karl.marlowe@eastlondon.nhs.uk
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Authors’ reply: Marlowe notes that the primary outcome of
our trial was relapse and comments that it is surprising, therefore,
that it was not analysed in more detail. McKenna et al attempt to
analyse the relapse data further. Neither Marlowe nor McKenna et
al appear to understand the inferential problems raised by the lack
of full or partial remission in a considerable proportion of the
patients in this trial. The number with full or partial remission
is itself an outcome of the trial (i.e. it is a post-randomisation
measure). Those who have shown no recovery are excluded from
the relapse data that Marlowe and McKenna et al present. In fact,
twice as many people show no recovery in TAU as in CBT (18:9).
The data reported by Marlowe and McKenna et al are therefore
not a causal effect of randomisation (i.e. not an intention-to-treat
effect). Because of this problem, we used months in full or partial
remission as our primary indicator of outcome for which a formal
intention-to-treat analysis is presented. This analysis and also a
further examination of total days in hospital and number of
admissions very clearly demonstrate that CBT, family intervention
and TAU do not differ. We also reported fully on deaths and other
adverse events and found no differences (the only completed
suicide was in TAU). We are therefore not at all convinced by
the suggestion that psychological intervention might be detrimental.
Indeed, we infer on the basis of the results of this trial and of
numerous meta-analyses (e.g. Pfammatter et al,1 Pilling et al2
and Wykes et al3) that CBT and family intervention are beneficial
for certain populations for a range of outcomes.
With respect to the point raised by Marlowe on the effects of
having a carer on a psychological intervention, we are of course
very aware of the Hogarty et al study,4,5 which we also discuss.
It reported mixed findings. Our point here concerned the
apparently beneficial effect of having a carer on CBT, which has
not been examined before.
1 Pfammatter M, Jungham UM, Brenner HD. Efficacy of psychological therapy
in schizophrenia: conclusions from meta-analyses. Schizophr Bull 2006; 32
(suppl 1): s64–80.
2 Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Orbach G, Morgan C.
Psychological treatments in schizophrenia: I. Meta-analysis of family
intervention and cognitive behaviour therapy. Psychol Med 2002; 32: 763–82.
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3 Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behaviour therapy for
schizophrenia: effect sizes, clinical models, and methodological rigor.
Schizophr Bull 2008; 34: 523–37.
4 Hogarty GE, Kornblith SJ, Greenwald P, DiBarry AL, Cooley S, Ulrich RF,
Carter M, Flesher S. Three years trials of personal therapy with
schizophrenics living with or independent of family. I: Description of study
and effects on relapse rates. Am J Psychiatry 1997; 154: 1504–13.
5 Hogarty GE, Greenwald P, Ulrich RF, Kornblith SJ, DiBarry AL, Cooley S,
Carter M, Flesher S. Three years trials of personal therapy with
schizophrenics living with or independent of family. II: Effects on adjustment
of patients. Am J Psychiatry 1997; 154: 1514–24.
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Community treatment orders are not a good thing. British Journal
of Psychiatry, 193, 96–100. Page 98, col. 2: Mary O’Hagan’s name
was misspelt. The relevant sentence should read: In the words of
Mary O’Hagan, who initiated the service user movement in
New Zealand and was the first chair of the World Network of
Users and Survivors in Psychiatry, ‘community treatment orders
are oppressive and corrupting – it’s tragic that other countries
are following Australia and New Zealand’s example’ (M. O’Hagan,
personal communication, 2007).
Computerised cognitive–behavioural therapy for depression:
systematic review. British Journal of Psychiatry, 193, 181–184.
The first sentence of the Acknowledgements (p. 183) should read:
This project was funded by the NIHR Health Technology Assess-
ment Programme (project ref. 04/01/01) and commissioned on
behalf of NICE. It has been published in full in Health Technology
Assessment, Vol. 10, No. 33.
doi: 10.1192/bjp.193.4.346
Corrections
Efficacy of antidepressants in juvenile depression: meta-analysis.
BJP, 193, 10–17. Page 12, Fig. 2: some minor errors (not affecting
the data reported) occurred in the published version of this figure.
The correct version appears below:















































































Fig. 2 Forest plot of rate ratios (RR, with 95% CI, on the
logarithmic scale) of responses to drug or placebo in 30
randomised double-blind placebo-controlled comparisons of rates
of ‘response’ to antidepressants v. placebo, with overall pooled
RR (1.22; 95% CI 1.15–1.31; blue diamond), based on meta-analysis.
Squares represent trials of serotonin reuptake inhibitors (SRIs; 12 trials); circles
represent tricyclic antidepressants (TCAs; 14 trials) and other types of antidepressants
(4 trials); the size of the data point is proportional to weight defined by study
participant number and measurement variance.
